| Malignant neoplasm of breast
Herceptin vs Aromasin
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Herceptin vs Aromasin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAromasin has a higher rate of injection site reactions vs Herceptin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Aromasin but not Herceptin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Herceptin
Aromasin
At A Glance
IV infusion
Weekly or every 3 weeks
HER2 antagonist
Oral
Daily
Aromatase inactivator
Indications
- Malignant neoplasm of breast
- Gastric Adenocarcinoma
- Adenocarcinoma of the gastroesophageal junction
- Malignant neoplasm of breast
- Advanced breast cancer
Dosing
Malignant neoplasm of breast (adjuvant) Schedule 1: 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly over 30 min for 12 or 18 weeks, then 6 mg/kg every 3 weeks to complete 52 weeks; Schedule 2: 8 mg/kg loading dose over 90 min IV, then 6 mg/kg every 3 weeks for 52 weeks.
Malignant neoplasm of breast (metastatic) 4 mg/kg loading dose as 90-min IV infusion, then 2 mg/kg weekly as 30-min IV infusions until disease progression.
Gastric Adenocarcinoma, Adenocarcinoma of the gastroesophageal junction 8 mg/kg loading dose over 90-min IV infusion, then 6 mg/kg over 30-90 min IV every 3 weeks until disease progression, in combination with cisplatin and capecitabine or 5-fluorouracil.
Malignant neoplasm of breast, Advanced breast cancer 25 mg orally once daily after a meal; increase to 50 mg once daily after a meal when administered with a strong CYP 3A4 inducer.
Contraindications
—
- Known hypersensitivity to exemestane or any excipient
Adverse Reactions
Most common Fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, myalgia
Serious Cardiomyopathy, infusion reactions, embryo-fetal toxicity, pulmonary toxicity, exacerbation of chemotherapy-induced neutropenia
Postmarketing Infusion reaction, oligohydramnios, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Most common (>=10%) Hot flushes, fatigue, arthralgia, headache, insomnia, increased sweating
Serious Cardiac ischemic events (myocardial infarction, angina, myocardial ischemia), cardiac failure, clinical fractures
Postmarketing Hypersensitivity, hepatitis including cholestatic hepatitis, paresthesia, tendon disorders including tendon rupture and tendonitis and tenosynovitis, acute generalized exanthematous pustulosis, urticaria, pruritus
Pharmacology
Humanized IgG1 kappa monoclonal antibody (anti-HER2) that inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) preferentially on HER2-overexpressing cancer cells.
Aromatase inactivator; exemestane is an irreversible steroidal aromatase inactivator that acts as a false substrate for the aromatase enzyme, binding irreversibly to the active site ('suicide inhibition') and significantly lowering circulating estrogen concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone biosynthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Herceptin
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (1/12) · Qty limit (0/12)
Aromasin
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Herceptin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Aromasin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Herceptin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Aromasin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Herceptin.
$0/fillfill
Aromasin Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HerceptinView full Herceptin profile
AromasinView full Aromasin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.